Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

License Agreement with Duke - Additional Information (Detail)

License Agreement with Duke - Additional Information (Detail)				3 Months Ended			6 Months Ended
	Feb. 17, 2023 USD ($) Patients	Feb. 04, 2022 USD ($)	Feb. 23, 2021 USD ($)	May 31, 2024 USD ($) ft² shares	Nov. 30, 2023 USD ($)	May 31, 2023 USD ($)	May 31, 2024 USD ($) ft² shares	May 31, 2023 USD ($)	Feb. 23, 2023 USD ($)	Feb. 28, 2021 USD ($)	Dec. 01, 2020 USD ($)
Patent Option And Technology License Agreement [Line Items]
Revenue				$ 8,042,811		$ 7,772,690	$ 15,895,046	$ 15,597,105
Impairment of assets					$ 13,108,064
Duke University [Member]
Patent Option And Technology License Agreement [Line Items]
License fee payable									$ 2,000,000		$ 12,000,000
Milestone payments first phase III clinical trial		$ 2,000,000	$ 2,000,000
Capitalized costs to obtain agreement										$ 15,372,382
Present value of license fee				12,000,000			12,000,000
Number of common stock value transferred				$ 3,585,172			$ 3,585,172
Number of common stock shares transferred \| shares				409,734			409,734
Capitalized costs amortization period				16 years			16 years
Amortization expense				$ 0		240,194	$ 0	480,387
Duke University [Member] \| 5.0% upon Execution of the Agreement [Member] \| Fully Diluted Equity Ownership
Patent Option And Technology License Agreement [Line Items]
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage			5.00%
Duke University [Member] \| 2.5% Market Cap [Member] \| Fully Diluted Equity Ownership
Patent Option And Technology License Agreement [Line Items]
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage			2.50%
Duke University [Member] \| Minimum [Member]
Patent Option And Technology License Agreement [Line Items]
Royalties Percentage Portion of Net Sales			7.00%
Duke University [Member] \| Minimum [Member] \| 2.5% Market Cap Triggers with 18 Months [Member] \| Fully Diluted Equity Ownership
Patent Option And Technology License Agreement [Line Items]
Average Closing Market Capital			$ 300,000,000
Duke University [Member] \| Minimum [Member] \| 2.5% Market Cap Triggers with 24 Months [Member] \| Fully Diluted Equity Ownership
Patent Option And Technology License Agreement [Line Items]
Average Closing Market Capital			$ 500,000,000
Duke University [Member] \| Maximum [Member]
Patent Option And Technology License Agreement [Line Items]
Royalties Percentage Portion of Net Sales			12.50%
Duke University [Member] \| Within Fourteen (14) days of February 23, 2021
Patent Option And Technology License Agreement [Line Items]
License fee payable			$ 10,000,000
Duke University [Member] \| Second Anniversary [Member]
Patent Option And Technology License Agreement [Line Items]
Minimum Annual Royalties Due Year Two			500,000
Minimum Annual Royalties Due Year Three			1,000,000
Minimum Annual Royalties Due Year Four			2,500,000
Minimum Annual Royalties Due Year Five			5,000,000
Minimum Annual Royalties Due After Year Five			$ 5,000,000
Duke University [Member] \| Third Anniversary [Member]
Patent Option And Technology License Agreement [Line Items]
Minimum Annual Royalties Due Year Three		500,000
Minimum Annual Royalties Due Year Four		1,000,000
Minimum Annual Royalties Due Year Five		2,500,000
Minimum Annual Royalties Due Year Six		5,000,000
Minimum Annual Royalties Due After Year Six		$ 5,000,000
Duke University [Member] \| Licensed Product and Licensed Process [Member]
Patent Option And Technology License Agreement [Line Items]
Area of medical condominium building \| ft²				56,000			56,000
Royalties Term							15 years
Duke University [Member] \| Licensed Product and Licensed Process [Member] \| 2.5% Upon Cumulative Net Sales [Member] \| Fully Diluted Equity Ownership
Patent Option And Technology License Agreement [Line Items]
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage			2.50%
Revenue			$ 10,000,000
Duke University [Member] \| Licensed Product and Licensed Process [Member] \| 2.5% Upon Cumulative Net Sales [Member] \| Fully Diluted Equity Ownership
Patent Option And Technology License Agreement [Line Items]
Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage			2.50%
Revenue			$ 75,000,000
Second Amendment to the License Agreement [Member]
Patent Option And Technology License Agreement [Line Items]
Payment towards funding and completion of study	$ 2,000,000
Research Agreement [Member]
Patent Option And Technology License Agreement [Line Items]
Additional Consideration Payable	2,000,000
Monthly Instalment payable	187,407
Consideration payable for research	$ 187,400
Number of patients in trial's targeted accrual \| Patients	137
Emmes Biopharma Services [Member]
Patent Option And Technology License Agreement [Line Items]
License fee				$ 6,352,291			$ 6,352,291
Payment due on execution				100,000			100,000
Management fee payable per month				21,862			$ 21,862
License fee payment completion term							53 months
Cost of trial estimated				20,000,000			$ 20,000,000
Emmes Biopharma Services [Member] \| Research And Development Expense [Member]
Patent Option And Technology License Agreement [Line Items]
Clinical trial expenses				$ 87,849		$ 0	$ 181,948	$ 0